華東醫藥(000963.SZ):控股子公司獲北京塞爾斯研發的寵物用中樞鎮痛藥物酒石酸布托啡諾注射液在中國的獨家經銷及市場推廣銷售權利
格隆匯10月9日丨華東醫藥(000963.SZ)公佈,2023年10月7日,公司全資子公司杭州中美華東製藥有限公司(以下簡稱"中美華東")的控股子公司江蘇南京農大動物藥業有限公司(以下簡稱"南農動藥")與動物藥品研發公司北京塞爾斯醫藥科技有限公司(以下簡稱"北京塞爾斯")簽署了產品《獨家經銷協議》。南農動藥獲得北京塞爾斯研發的寵物用中樞鎮痛藥物酒石酸布托啡諾注射液(商品名:保適寧®,以下簡稱"標的產品")在中國的獨家經銷及市場推廣銷售權利。根據協議約定,《獨家經銷協議》自北京塞爾斯與杭州福廣鴻信股權投資合夥企業(有限合夥)(以下簡稱"福廣鴻信")簽訂股權投資協議之日起正式生效。
2023年10月7日,福廣鴻信與北京塞爾斯簽署《投資協議》,福廣鴻信投資人民幣2000萬元,向北京塞爾斯增資,完成投資後福廣鴻信將持有北京塞爾斯20%股權。同日,《獨家經銷協議》正式生效(以下簡稱"本次交易")。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.